199 related articles for article (PubMed ID: 12414617)
1. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line.
Ricci C; Scappini B; Divoky V; Gatto S; Onida F; Verstovsek S; Kantarjian HM; Beran M
Cancer Res; 2002 Nov; 62(21):5995-8. PubMed ID: 12414617
[TBL] [Abstract][Full Text] [Related]
2. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
[TBL] [Abstract][Full Text] [Related]
3. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
[TBL] [Abstract][Full Text] [Related]
5. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
6. [Tyrosine kinase inhibitor STI571: new possibility in the treatment of chronic myeloid leukemia].
Molnár L; Losonczy H
Orv Hetil; 2002 Oct; 143(42):2379-84. PubMed ID: 12440260
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
[TBL] [Abstract][Full Text] [Related]
8. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.
Ohmine K; Nagai T; Tarumoto T; Miyoshi T; Muroi K; Mano H; Komatsu N; Takaku F; Ozawa K
Stem Cells; 2003; 21(3):315-21. PubMed ID: 12743326
[TBL] [Abstract][Full Text] [Related]
9. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571).
La Rosée P; Corbin AS; Stoffregen EP; Deininger MW; Druker BJ
Cancer Res; 2002 Dec; 62(24):7149-53. PubMed ID: 12499247
[TBL] [Abstract][Full Text] [Related]
10. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R
Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961
[TBL] [Abstract][Full Text] [Related]
11. A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.
Huron DR; Gorre ME; Kraker AJ; Sawyers CL; Rosen N; Moasser MM
Clin Cancer Res; 2003 Apr; 9(4):1267-73. PubMed ID: 12684394
[TBL] [Abstract][Full Text] [Related]
12. Cytogenetic and molecular mechanisms of resistance to imatinib.
Hochhaus A
Semin Hematol; 2003 Apr; 40(2 Suppl 2):69-79. PubMed ID: 12783379
[TBL] [Abstract][Full Text] [Related]
13. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
Ernst T; Erben P; Müller MC; Paschka P; Schenk T; Hoffmann J; Kreil S; La Rosée P; Hehlmann R; Hochhaus A
Haematologica; 2008 Feb; 93(2):186-92. PubMed ID: 18223278
[TBL] [Abstract][Full Text] [Related]
14. Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes.
Czechowska A; Poplawski T; Drzewoski J; Blasiak J
Chem Biol Interact; 2005 Apr; 152(2-3):139-50. PubMed ID: 15840387
[TBL] [Abstract][Full Text] [Related]
15. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
Gorre ME; Mohammed M; Ellwood K; Hsu N; Paquette R; Rao PN; Sawyers CL
Science; 2001 Aug; 293(5531):876-80. PubMed ID: 11423618
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines.
van der Kuip H; Moehring A; Wohlbold L; Miething C; Duyster J; Aulitzky WE
Leuk Res; 2004 Apr; 28(4):405-8. PubMed ID: 15109541
[TBL] [Abstract][Full Text] [Related]
17. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
Mishra S; Zhang B; Cunnick JM; Heisterkamp N; Groffen J
Cancer Res; 2006 May; 66(10):5387-93. PubMed ID: 16707466
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias.
Shah NP; Sawyers CL
Oncogene; 2003 Oct; 22(47):7389-95. PubMed ID: 14576846
[TBL] [Abstract][Full Text] [Related]
19. [The monitoring of residual disease for chronic myelogenous leukemia patients treated with imatinib mesylate: detection of T315I mutation in ATP binding site of BCR/ABL gene].
Miyanishi S; Umeki K; Hayashi T; Fukutsuka K; Okumura A; Kishimori C
Rinsho Byori; 2003 Oct; 51(10):1023-9. PubMed ID: 14653203
[TBL] [Abstract][Full Text] [Related]
20. Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.
Barthe C; Gharbi MJ; Lagarde V; Chollet C; Cony-Makhoul P; Reiffers J; Goldman JM; Melo JV; Mahon FX
Br J Haematol; 2002 Oct; 119(1):109-11. PubMed ID: 12358910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
